Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Enrichment of 57Fe isotope in neutron flux of nuclear reactors observed by Mössbauer spectroscopy.

Sawicki JA.

Appl Radiat Isot. 2018 Feb;132:200-205. doi: 10.1016/j.apradiso.2017.11.024. Epub 2017 Nov 17.

PMID:
29221630
2.

Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development.

Peng W, Furuuchi N, Aslanukova L, Huang YH, Brown SZ, Jiang W, Addya S, Vishwakarma V, Peters E, Brody JR, Dixon DA, Sawicki JA.

Mol Cell Biol. 2018 Jan 16;38(3). pii: e00427-17. doi: 10.1128/MCB.00427-17. Print 2018 Feb 1.

3.

HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR.

Mol Cancer Res. 2016 Jul;14(7):599-611. doi: 10.1158/1541-7786.MCR-15-0448. Epub 2016 Apr 6.

4.

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.

Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA.

Oncotarget. 2016 Apr 19;7(16):21812-24. doi: 10.18632/oncotarget.7840.

5.

Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.

Huang YH, Peng W, Furuuchi N, Gerhart J, Rhodes K, Mukherjee N, Jimbo M, Gonye GE, Brody JR, Getts RC, Sawicki JA.

Cancer Res. 2016 Mar 15;76(6):1549-59. doi: 10.1158/0008-5472.CAN-15-2073. Epub 2016 Feb 26. Erratum in: Cancer Res. 2016 Jun 1;76(11):3437.

6.

The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR.

Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21.

PMID:
26387536
7.

Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.

Jimbo M, Blanco FF, Huang YH, Telonis AG, Screnci BA, Cosma GL, Alexeev V, Gonye GE, Yeo CJ, Sawicki JA, Winter JM, Brody JR.

Oncotarget. 2015 Sep 29;6(29):27312-31. doi: 10.18632/oncotarget.4743.

8.

MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.

Tholey RM, Lal S, Jimbo M, Burkhart RA, Blanco FF, Cozzitorto JA, Eisenberg JD, Jiang W, Iacobuzio-Donahue CA, Witkiewicz AK, Glbert M, Yeo CJ, Brody JR, Sawicki JA, Winter JM.

Mol Cancer Res. 2015 Mar;13(3):439-48. doi: 10.1158/1541-7786.MCR-14-0199. Epub 2014 Oct 21.

9.

HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.

Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR.

Cancer Res. 2014 Feb 15;74(4):1128-40. doi: 10.1158/0008-5472.CAN-13-1915.

10.

Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.

Burkhart RA, Peng Y, Norris ZA, Tholey RM, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, Sawicki JA, Zhuang Z, Brody JR.

Mol Cancer Res. 2013 Aug;11(8):901-11. doi: 10.1158/1541-7786.MCR-12-0699. Epub 2013 May 21.

11.

Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box".

Tholey R, Sawicki JA, Brody JR.

Cancer J. 2012 Nov-Dec;18(6):665-73. doi: 10.1097/PPO.0b013e3182793ff6. Review.

PMID:
23187855
12.

DNA nanotherapy for pre-neoplastic cervical lesions.

Peng W, Dunton C, Holtz D, Parva M, Stampler K, Forwood M, Gogoi R, Lace MJ, Anderson DG, Sawicki JA.

Gynecol Oncol. 2013 Jan;128(1):101-106. doi: 10.1016/j.ygyno.2012.10.018. Epub 2012 Oct 23.

PMID:
23103931
13.

Disruption of Abi1/Hssh3bp1 expression induces prostatic intraepithelial neoplasia in the conditional Abi1/Hssh3bp1 KO mice.

Xiong X, Chorzalska A, Dubielecka PM, White JR, Vedvyas Y, Hedvat CV, Haimovitz-Friedman A, Koutcher JA, Reimand J, Bader GD, Sawicki JA, Kotula L.

Oncogenesis. 2012 Sep 3;1:e26. doi: 10.1038/oncsis.2012.28.

14.

Essential role for Abi1 in embryonic survival and WAVE2 complex integrity.

Dubielecka PM, Ladwein KI, Xiong X, Migeotte I, Chorzalska A, Anderson KV, Sawicki JA, Rottner K, Stradal TE, Kotula L.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7022-7. doi: 10.1073/pnas.1016811108. Epub 2011 Apr 11.

15.

Epithelial cell-targeted transgene expression enables isolation of cyan fluorescent protein (CFP)-expressing prostate stem/progenitor cells.

Peng W, Bao Y, Sawicki JA.

Transgenic Res. 2011 Oct;20(5):1073-86. doi: 10.1007/s11248-010-9478-2. Epub 2011 Jan 11.

16.

CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapy.

Huang YH, Cozzitorto JA, Richards NG, Eltoukhy AA, Yeo CJ, Langer R, Anderson DG, Brody JR, Sawicki JA.

Cancer Biol Ther. 2010 Nov 1;10(9):878-84. doi: 10.4161/cbt.10.9.13234. Epub 2010 Nov 1.

17.

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice.

Huang YH, Zugates GT, Peng W, Holtz D, Dunton C, Green JJ, Hossain N, Chernick MR, Padera RF Jr, Langer R, Anderson DG, Sawicki JA.

Cancer Res. 2009 Aug 1;69(15):6184-91. doi: 10.1158/0008-5472.CAN-09-0061.

18.

Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis.

Huang YH, Bao Y, Peng W, Goldberg M, Love K, Bumcrot DA, Cole G, Langer R, Anderson DG, Sawicki JA.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3426-30. doi: 10.1073/pnas.0813348106. Epub 2009 Feb 10.

19.

Fetal microchimerism and cancer.

Sawicki JA.

Cancer Res. 2008 Dec 1;68(23):9567-9. doi: 10.1158/0008-5472.CAN-08-3008. Review.

20.

Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells.

Showalter SL, Huang YH, Witkiewicz A, Costantino CL, Yeo CJ, Green JJ, Langer R, Anderson DG, Sawicki JA, Brody JR.

Cancer Biol Ther. 2008 Oct;7(10):1584-90. Epub 2008 Oct 3.

21.

Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy.

Sawicki JA, Anderson DG, Langer R.

Adv Exp Med Biol. 2008;622:209-19. doi: 10.1007/978-0-387-68969-2_17. Review.

PMID:
18546630
22.

Rapid Optimization of Gene Delivery by Parallel End-modification of Poly(β-amino ester)s.

Zugates GT, Peng W, Zumbuehl A, Jhunjhunwala S, Huang YH, Langer R, Sawicki JA, Anderson DG.

Mol Ther. 2007 Jul;15(7):1306-1312. doi: 10.1038/sj.mt.6300132. Epub 2016 Dec 7.

PMID:
28182918
23.

Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors.

Peng W, Anderson DG, Bao Y, Padera RF Jr, Langer R, Sawicki JA.

Prostate. 2007 Jun 1;67(8):855-62.

PMID:
17427200
24.

Rapid optimization of gene delivery by parallel end-modification of poly(beta-amino ester)s.

Zugates GT, Peng W, Zumbuehl A, Jhunjhunwala S, Huang YH, Langer R, Sawicki JA, Anderson DG.

Mol Ther. 2007 Jul;15(7):1306-12. Epub 2007 Mar 20.

25.

Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.

Peng W, Chen J, Huang YH, Sawicki JA.

Gene Ther. 2005 Nov;12(21):1573-80.

PMID:
16034457
26.

Human coxsackie adenovirus receptor (CAR) expression in transgenic mouse prostate tumors enhances adenoviral delivery of genes.

Bao Y, Peng W, Verbitsky A, Chen J, Wu L, Rauen KA, Sawicki JA.

Prostate. 2005 Sep 1;64(4):401-7.

PMID:
15761871
27.

A polymer library approach to suicide gene therapy for cancer.

Anderson DG, Peng W, Akinc A, Hossain N, Kohn A, Padera R, Langer R, Sawicki JA.

Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16028-33. Epub 2004 Nov 1.

28.

Capturing and profiling adult hair follicle stem cells.

Morris RJ, Liu Y, Marles L, Yang Z, Trempus C, Li S, Lin JS, Sawicki JA, Cotsarelis G.

Nat Biotechnol. 2004 Apr;22(4):411-7. Epub 2004 Mar 14.

PMID:
15024388
29.

Overexpression of a dominant-negative ornithine decarboxylase in mouse skin: effect on enzyme activity and papilloma formation.

Shantz LM, Guo Y, Sawicki JA, Pegg AE, O'Brien TG.

Carcinogenesis. 2002 Apr;23(4):657-64.

PMID:
11960919
30.

Targeted expression of spermidine/spermine N1-acetyltransferase increases susceptibility to chemically induced skin carcinogenesis.

Coleman CS, Pegg AE, Megosh LC, Guo Y, Sawicki JA, O'Brien TG.

Carcinogenesis. 2002 Feb;23(2):359-64.

PMID:
11872645
31.

Evidence for stem cells in cultures of mouse prostate epithelial cells.

Sawicki JA, Rothman CJ.

Prostate. 2002 Jan 1;50(1):46-53.

PMID:
11757035
32.

K6/ODC transgenic mice as a sensitive model for carcinogen identification.

Chen Y, Megosh LC, Gilmour SK, Sawicki JA, O'Brien TG.

Toxicol Lett. 2000 Jul 27;116(1-2):27-35.

PMID:
10906419
33.

Cell-specific ecdysone-inducible expression of FLP recombinase in mammalian cells.

Sawicki JA, Monks B, Morris RJ.

Biotechniques. 1998 Nov;25(5):868-70, 872-5.

34.

A composite CMV-IE enhancer/beta-actin promoter is ubiquitously expressed in mouse cutaneous epithelium.

Sawicki JA, Morris RJ, Monks B, Sakai K, Miyazaki J.

Exp Cell Res. 1998 Oct 10;244(1):367-9.

PMID:
9770380
35.

Sibling rivalry and the new baby: anticipatory guidance and management strategies.

Sawicki JA.

Pediatr Nurs. 1997 May-Jun;23(3):298-302. Review.

PMID:
9220807
36.

Elements in the murine c-mos messenger RNA 5'-untranslated region repress translation of downstream coding sequences.

Steel LF, Telly DL, Leonard J, Rice BA, Monks B, Sawicki JA.

Cell Growth Differ. 1996 Oct;7(10):1415-24.

37.

Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase.

Megosh L, Gilmour SK, Rosson D, Soler AP, Blessing M, Sawicki JA, O'Brien TG.

Cancer Res. 1995 Oct 1;55(19):4205-9.

38.

Minerals associated with biofilms occurring on exposed rock in a granitic underground research laboratory.

Brown DA, Kamineni DC, Sawicki JA, Beveridge TJ.

Appl Environ Microbiol. 1994 Sep;60(9):3182-91.

39.

Effects of exogenous putrescine on murine preimplantation development in vitro.

Sawicki JA, Impellizeri A, O'Brien TG.

Dev Biol. 1991 Dec;148(2):620-4.

PMID:
1743405
40.

Cellular protein differences between nontumorigenic Ad5 and tumorigenic Ad12 transformed mouse cells.

Eager KB, Sawicki JA, Ricciardi RP.

Virology. 1986 Jul 30;152(2):487-91.

PMID:
3727404
41.

Identical RT1 class II molecules are expressed by rat RT1m and RT1c haplotypes.

Sawicki JA, Frelinger JG, Palmer M, Buck DA, Dietzschold B, Wettstein PJ.

J Immunol. 1985 Oct;135(4):2853-8.

PMID:
3839806
42.

Evidence for extensive polymorphism of RT1 Class II molecules in the rat.

Sawicki JA, Wettstein PJ.

J Immunol. 1984 Jan;132(1):310-5.

PMID:
6418802
43.

Beta 2-microglobulin.

Appella E, Sawicki JA.

Methods Enzymol. 1984;108:494-504. No abstract available.

PMID:
6396488
44.

Production of viable adult trisomy 17 reversible diploid mouse chimeras.

Epstein CJ, Smith SA, Zamora T, Sawicki JA, Magnuson TR, Cox DR.

Proc Natl Acad Sci U S A. 1982 Jul;79(14):4376-80.

45.

Assignment of the gene for beta 2-microglobulin (B2m) to mouse chromosome 2.

Cox DR, Sawicki JA, Yee D, Appella E, Epstein CJ.

Proc Natl Acad Sci U S A. 1982 Mar;79(6):1930-4.

46.

Evidence for expression of the paternal genome in the two-cell mouse embryo.

Sawicki JA, Magnuson T, Epstein CJ.

Nature. 1981 Dec 3;294(5840):450-1. No abstract available.

PMID:
6171732
47.

H-2 antigens as genetic markers: a two-dimensional gel electrophoretic study.

Sawicki JA, Epstein CJ.

Immunogenetics. 1981;12(1-2):141-51.

PMID:
6162790
49.

Synthesis of ovarian acid phosphatase-1 in Drosophila melanogaster.

Sawicki JA, MacIntyre RJ.

Dev Biol. 1977 Oct 1;60(1):1-13. No abstract available.

PMID:
409635

Supplemental Content

Loading ...
Support Center